值得注意的是，港股创新药板块今年整体表现亮眼，港股创新药ETF（159567）年内累计涨幅超95%， 连续8个月获资金净流入，份额突破81亿份连创新高。 港股创新药ETF（159567）跟踪国证港股通创新药指数，旨在反映港股通范围内创新药领域上市公司的 运行特征。 场外投资者还可通过港股创新药ETF联接基金（A类：023929，C类：023930）一键布局港股创新药板 块上行机遇。 港股今日早盘震荡调整，恒生指数跌超1%，创新药板块盘中探底回升，港股创新药ETF（159567）逆 势涨近1%。成分股中，康诺亚-B、石药集团、百济神州、远大医药涨超2%。 有分析认为，在创新药政策支持下，新上市产品有望快速实现商业价值，伴随着国家全链条鼓励创新药 政策的落地，国产创新药在院内产品的占比还会快速提升，有望成为成长性最好的细分板块。此外，从 中报业绩来看，创新药、CXO、生物制药等医药行业细分板块均迎来业绩修复。目前，板块具有"创新 升级+盈利拐点+出海BD常态化"三重逻辑，这三重逻辑将持续支撑后续行情。 ...

Core Viewpoint - The innovative drug sector has shown strong performance in the first half of the year, driven by successful collaborations, excellent clinical data, and supportive policies, despite recent declines in various indices related to the sector [1]. Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index fell by 4.4% [1] - The CSI Innovative Drug Industry Index decreased by 4.2% [1] - The CSI Biotechnology Theme Index dropped by 4.1% [1] - The CSI Pharmaceutical and Health Comprehensive Index declined by 4% [1] - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index fell by 3.9% [1] - The Everbright Innovative Drug ETF (159316) saw a net subscription of 116 million shares today [1] Group 2: Sector Insights - The innovative drug sector is expected to rapidly realize commercial value for newly launched products due to national policies encouraging innovation [1] - The proportion of domestic innovative drugs in hospital products is anticipated to increase quickly, positioning it as one of the best growth segments [1]

Group 1 - The core viewpoint of the news highlights the strong performance of the innovative drug sector in the first half of the year, driven by successful collaborations, excellent clinical data, and supportive policies [1] - The China Securities report indicates that the innovative drug sector is expected to see a rapid increase in the commercial value of newly launched products due to national policies encouraging innovation [1] - The proportion of domestic innovative drugs in hospital products is anticipated to rise quickly, positioning this sector as one of the best growth segments [1] Group 2 - The index focuses on leading innovative drug companies in the A-share market, consisting of no more than 50 stocks involved in innovative drug research and development [4] - The index has shown a rolling price-to-earnings ratio of 59.2 times and an increase of 91.3% since its inception [5] - The biotechnology ETF tracks the China Biotechnology Theme Index, which includes up to 50 stocks related to gene diagnostics, biopharmaceuticals, and other human biotechnology [6] Group 3 - The healthcare ETF tracks the CSI 300 Healthcare Index, covering leading companies in the healthcare sector, including chemical pharmaceuticals, medical services, and medical devices [8] - The CSI 300 Healthcare Index has a rolling price-to-earnings ratio of 33.9 times and has increased by 65.7% since its inception [9]

Core Viewpoint - The Hong Kong innovative drug sector is showing resilience, with the Hang Seng Innovative Drug Index rising by 1.6% and significant trading activity in the Hang Seng Innovative Drug ETF, indicating strong investor interest and growth potential in this segment [1] Industry Performance - The innovative drug companies in Hong Kong reported rapid revenue growth in the first half of the year, with BeiGene achieving revenue of 17.52 billion, a year-on-year increase of 46.0%; Innovent Biologics reaching 6.19 billion, up 45.6%; and CanSino Biologics reporting 1.41 billion, a growth of 32.6% [1] - The performance of the innovative drug sector is driven by successful overseas collaborations, positive clinical data releases, and supportive policies, positioning it as a high-growth segment within the market [1] Market Dynamics - The recent adjustment of the Hang Seng Innovative Drug Index, which now excludes contract research organizations (CROs), enhances its purity and accuracy in reflecting the performance of innovative drug companies in China [1] - The Hang Seng Innovative Drug ETF is currently the only product tracking this adjusted index, providing investors with a targeted opportunity to capitalize on the growth of the innovative drug industry [1]

渤海证券指出，近期医药生物板块大幅上涨，创新药和CXO行情延续，催化不断。政策方面，本月出 台《支持创新药高质量发展的若干措施》及《关于开展第十一批国家组织药品集中采购相关药品信息填 报工作的通知》，从研发、准入、支付等全链条支持创新药发展，对制药及器械板块意义重大。业绩方 面，已披露业绩的CXO头部企业均有较好表现，呈现恢复态势，板块业绩拐点有望到来。展望后续， 建议把握创新药政策支持窗口，关注商保创新药目录推出进程；同时第十一批集采正在开展，规则进一 步优化，关注受益于集采规则优化的制药板块。 每日经济新闻 科创创新药ETF国泰（589720）跟踪的是科创新药指数（950161），单日涨跌幅可达20%。该指数从科 技创新领域筛选专注于新药研发的上市公司证券作为指数样本，涵盖生物医药、化学制药等细分领域。 指数重点选取研发投入强度大、创新能力突出的医药企业，旨在反映中国创新药物行业领军企业在资本 市场的整体表现。 注：如提及个股仅供参考，不代表投资建议。指数/基金短期涨跌幅及历史表现仅供分析参考，不预示 未来表现。市场观点随市场环境变化而变动，不构成任何投资建议或承诺。文中提及指数仅供参考，不 构成任何投资 ...

【为什么说，此轮修订是一次"提纯"？】 修订最大的变化，在于选样空间的调整。修订前，选样标准为"公司业务涉及创新药研发、生产等领 域"。而修订后，要求"公司主营业务涉及创新药研发、生产等领域，不含医药外包服务"。此外，样本 股定期调整规则由半年度调整修订为季度定期调整。本次修订将于2025年8月12日实施。 【"100%创新药"的含金量有多高？】 ETF跟随指数配置一篮子股票，而"纯度"对于指数而言至关重要，不仅能够最大化捕捉行业的上涨红 利，而且可避免相关度低成分所带来的稀释效应，更纯粹地获取收益。 "100%创新药"的含金量，在于剔除了CXO的影响。追根溯源，CXO的商业模式与创新药存在本质差 异，因此剔除CXO能减小其对创新药的扰动，从而更好地攫取收益。 CXO（Contract X Organization）是对医药外包服务组织的统称，CXO提供研发、生产等外包服务，收 入依赖订单合同，本质是"服务商"。而创新药通过自主研发获取药品知识产权（IP），核心收入来自专 利授权（如License-out）或药品销售分成。对比来看，创新药直接受益于药品商业化的成功，能够分享 药品上市后的高额专利收益；而CXO ...

Core Viewpoint - The article emphasizes the positive impact of recent policy changes in China's healthcare sector, particularly regarding drug procurement and innovation, which are expected to enhance the industry's growth momentum and lead to a revaluation of quality enterprises [5]. Market Review - Last week, the A-share pharmaceutical and biotechnology index rose by 1.90%, outperforming the CSI 300 index by 0.21 percentage points but underperforming the ChiNext index by 0.24 percentage points, ranking 19th among 31 sub-industries [3]. - The Hong Kong Hang Seng Healthcare Index increased by 0.84%, lagging behind the Hang Seng China Enterprises Index by 0.99 percentage points [3]. Company R&D Progress Tracking - Last week, Yiling Pharmaceutical's IND application for YL-13027 tablets was newly undertaken, and Kangnuo's clinical application for CM512 injection was also newly undertaken [4]. - Heng Rui Pharmaceutical's SHR-1819 is currently in Phase III clinical trials, while Kanghong Pharmaceutical's KH607 and Fuhong Hanlin's HLX43 are in Phase II clinical trials, and Kelun Bo Tai's SKB107 is in Phase I clinical trials [4]. Weekly Perspective - The optimization of drug procurement policies is reshaping the industry ecosystem, allowing quality enterprises to undergo value reassessment. The 11th batch of drug procurement rules emphasizes principles such as "stabilizing clinical use, ensuring quality, preventing collusion, and countering internal competition" [5]. - The support for innovative drugs is characterized by a "full chain, high intensity" approach, with 402 new drugs included in the medical insurance catalog since the 14th Five-Year Plan began. The expenditure on innovative drugs in 2024 is projected to reach 3.9 times that of 2020, with an annual growth rate of 40% [5].

Group 1: Market Performance - The Shanghai Composite Index experienced a strong upward trend, with the index closing up 0.65% at 3605.73 points, while the Shenzhen Component Index rose 1.21% to 11193.06 points, and the ChiNext Index increased by 1.5% to 2345.37 points [1] - The total trading volume in the Shanghai, Shenzhen, and Beijing markets reached 187.42 billion yuan, a decrease of 24.5 billion yuan from the previous day [1] Group 2: Policy and Industry Insights - The "anti-involution" policy is gaining momentum, which is expected to become a sustained investment theme, focusing on the construction of a unified national market and optimizing performance assessment mechanisms for high-quality production [1] - The government has introduced multiple policies to support innovative drugs, with the establishment of a dual-directory model for basic medical insurance and commercial health insurance, which is expected to enhance the commercialization of innovative drugs [2][3] - The establishment of a commercial health insurance directory for innovative drugs is anticipated to provide a supplementary payment channel for drugs not included in the national medical insurance directory, accelerating the commercialization process of innovative results [3] Group 3: Agricultural and Financial Policies - The Ministry of Agriculture and Rural Affairs emphasized the need for further policy measures to prevent significant fluctuations in production and prices in the pig industry, aiming to enhance the overall quality and competitiveness of the industry [3] - The People's Bank of China and the Ministry of Agriculture and Rural Affairs issued opinions to increase financial resources for rural revitalization, encouraging financial institutions to support modern rural industries and promote investment in rural development [4] Group 4: State-Owned Enterprises and Data Innovation - The State-owned Assets Supervision and Administration Commission (SASAC) is focusing on high-quality reforms of state-owned enterprises, promoting the optimization of state capital allocation and resisting "involution" competition [5][6] - The National Data Bureau held a meeting to promote the innovative development of local data groups, aiming to enhance service capabilities and support the development of a unified national data market [6] Group 5: Smart Vehicle Development - Shanghai plans to issue demonstration operation licenses for intelligent connected vehicles during the 2025 World Artificial Intelligence Conference, allowing public access to Robotaxi services within designated areas [7]

截至2025年7月22日 09:47，恒生医疗保健指数(HSHCI)强势上涨2.14%，成分股丽珠医药(01513)上涨11.57%，联邦制药(03933)上涨7.00%，再鼎医药(09688) 上涨6.03%，博安生物(06955)，金斯瑞生物科技(01548)等个股跟涨。恒生医疗ETF(513060)上涨2.02%，最新价报0.66元。拉长时间看，截至2025年7月21 日，恒生医疗ETF近1周累计上涨8.95%，涨幅排名可比基金1/3。 流动性方面，恒生医疗ETF盘中换手10.09%，成交8.40亿元，市场交投活跃。拉长时间看，截至7月21日，恒生医疗ETF近1周日均成交28.22亿元，排名可比 基金第一。 第十一批国家药品集采正式启动，共涉及55个品种，释放出集采政策向创新药倾斜的积极信号。中信建投证券指出，本次集采坚持"新药不集采、集采非新 药"的原则，并进一步优化了品种遴选条件，包括排除协议期内的医保谈判药品、专利侵权风险高的品种以及年采购额低于1亿元的品种，体现出政策对创新 药的保护力度不断增强。同时，集采规则更加注重"稳临床、保质量、防围标、反内卷"，通过品牌报量机制、价差控制优化、低价声明制 ...

Core Viewpoint - The rise of innovative drugs in China is reshaping the global pharmaceutical landscape, driven by lower costs and higher efficiency, leading to significant commercial breakthroughs and increased foreign interest in Chinese innovative assets [1] Group 1: Innovative Drug Business Development (BD) - In 2024, over 100 external authorization transactions occurred in China's biopharmaceutical sector, with a total disclosed transaction value of approximately $52.3 billion (+25%), marking a historical high [2] - By June 12, 2025, the cumulative BD transaction value reached $50.1 billion (+135%), with 3SBio authorizing its PD-1/VEGF dual antibody SSGJ-707 to Pfizer for a total of $6.05 billion [2] Group 2: Commercialization Breakthroughs - A selection of 56 A-share Sci-Tech Innovation Board and 53 Hong Kong 18A innovative drug companies showed an increasing trend in profitability, with 58.9% and 73.6% respectively reporting "profit increase," "turning losses into profits," or "maintaining or reducing losses" in 2024, compared to 44.6% and 69.8% in 2023 [3] Group 3: Supportive Policies - The innovative drug sector was included in the government work report for the first time in 2024, with the State Council approving the "Implementation Plan for Full-Chain Support of Innovative Drug Development" on July 5, 2024, and the Shanghai Municipal Government releasing supportive opinions for the biopharmaceutical industry on July 30, 2024 [4] Group 4: CXO and Upstream Developments - The industry environment shows stable funding for innovation, with multinational corporations (MNCs) increasing R&D investments and maintaining steady medical financing, while BD transactions facilitate capital turnover for domestic pharmaceutical companies [5] - Emerging fields like peptides and ADCs are becoming R&D hotspots, with external CXOs achieving growth above the industry average, while internal CXOs are stabilizing, suggesting a focus on leading companies with strong capabilities and market share [5] Group 5: Medical Devices - Since 2025, numerous equipment upgrade projects have entered the bidding phase, driving recovery growth in the overall equipment industry, with expectations for continued high demand in 2025 as inventory levels are gradually digested [6]